http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Nov 2025 15:41:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html <p>BioVaxys Technology Corp. (CSE: BIOV) completed a private placement financing that raised $1,922,984.92 in gross proceeds through the sale of 11,311,676 units at $0.17 per unit.</p> <p>Each unit consists of one common share and one warrant that allows the holder to purchase an additional share at $0.40 for 24 months from the issuance date. The company used the Listed Issuer Financing Exemption under Canadian securities regulations for the offering, which means the units are not subject to resale restrictions.</p> <p>The Vancouver-based biopharmaceutical company stated the proceeds will fund pipeline growth activities including pursuing licensing opportunities and research collaborations, identifying supply sources for http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html Wed, 19 Nov 2025 15:41:15 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html <p>BioVaxys Technology Corp. (CSE: BIOV) completed a private placement financing that raised $1,922,984.92 in gross proceeds through the sale of 11,311,676 units at $0.17 per unit.</p> <p>Each unit consists of one common share and one warrant that allows the holder to purchase an additional share at $0.40 for 24 months from the issuance date. The company used the Listed Issuer Financing Exemption under Canadian securities regulations for the offering, which means the units are not subject to resale restrictions.</p> <p>The Vancouver-based biopharmaceutical company stated the proceeds will fund pipeline growth activities including pursuing licensing opportunities and research collaborations, identifying supply sources for http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html Wed, 19 Nov 2025 15:41:15 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html <p>BioVaxys Technology Corp. (CSE: BIOV) completed a private placement financing that raised $1,922,984.92 in gross proceeds through the sale of 11,311,676 units at $0.17 per unit.</p> <p>Each unit consists of one common share and one warrant that allows the holder to purchase an additional share at $0.40 for 24 months from the issuance date. The company used the Listed Issuer Financing Exemption under Canadian securities regulations for the offering, which means the units are not subject to resale restrictions.</p> <p>The Vancouver-based biopharmaceutical company stated the proceeds will fund pipeline growth activities including pursuing licensing opportunities and research collaborations, identifying supply sources for http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html Wed, 19 Nov 2025 15:41:15 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Press+Releases/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html <p class="bwalignc"> <b><i>// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //</i></b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“<b>BioVaxys</b>” or the “<b>Company</b>”) announces that it has closed its previously announced non-brokered private placement financing (the “<b>Offering</b>”) of 11,311,676 units of the Company (the “<b>Units</b>”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. </p><p> Each Unit consists of one common share of the Company (“<b>Share</b>”) and one common share purchase warrant (“<b>Warrant</b>”), whereby each Warrant will entitle the holder thereof to acquire one additional http://www.streetinsider.com/Business+Wire/BioVaxys+Technology+Corp.+Closes+Listed+Issuer+Financing+Exemption+%28LIFE%29+Private+Placement/25638005.html Wed, 19 Nov 2025 15:41:00 -0400 5LB BIOV O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/Press+Releases/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729 http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/us.wi.madisn" idsrc="xmltag.org" >MADISON, Wis.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2025</chron></span> /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span>") and SpayVac for <span>Wildlife, Inc.</span> are pleased to announce that results from a collaborative research project conducted in the <location>Bavarian Forest National Park</location> in <location value="LC/de" idsrc="xmltag.org" >Germany</location> have recently been published in the <i><a http://www.streetinsider.com/PRNewswire/BioVaxys+Licensee+SpayVac-for-Wildlife%2C+Inc.%2C+Reports+Further+Positive+Single-Dose+Efficacy+Data+for+Its+Immunocontraceptive+Vaccine+and+Initiation+of+Regulatory+Submission+Process/25450652.html Tue, 14 Oct 2025 08:00:00 -0400 5LB 5LB 5LB 5LB 5LB0 5LB0 5LB0 5LB0 BIOV BVAXD BVAXF O.41051729